CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests
Roche experts discuss the company’s recently launched automated solution and how it will bring mass spec to more patients
ACLA president Susan Van Meter discusses some of the key issues labs faced in 2024, along with work to address these developments through 2025